The Endocannabinoid System as a Target for Obesity Treatment

Després, 2001, Treatment of obesity: Need to focus on high risk abdominally obese patients, BMJ, 322, 716, 10.1136/bmj.322.7288.716 Després, 2006, Abdominal obesity and metabolic syndrome, Nature, 444, 881, 10.1038/nature05488 Cota, 2007, CB1 receptors: Emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health, Diabetes Metab Res Rev, 23, 507, 10.1002/dmrr.764 US Dept of Health and Human Services, 2001 US Dept of Health and Human Services. National Center for Health Statistics. Health, United States, 2007 with Chartbook on Trends in the Health of Americans. Hyattsville, Md: 2007:9. http://www.cdc.gov/nchs/data/hus/hus07acc.pdf. Accessed July 31, 2008. Consensus Report of the American Osteopathic Association, 2008, Addressing overweight and obesity: Evolving to a medical consensus, JAOA, 108, S2 Ford, 2004, Increasing prevalence of the metabolic syndrome among U.S. adults, Diabetes Care, 27, 2444, 10.2337/diacare.27.10.2444 Bastard, 2006, Recent advances in the relationship between obesity, inflammation, and insulin resistance, Eur Cytokine Netw, 17, 4 Despres, 2006, Abdominal obesity: The most prevalent cause of the metabolic syndrome and related cardiometabolic risk, Eur Heart J, 8, B4, 10.1093/eurheartj/sul002 Eckel, 2005, The metabolic syndrome, Lancet, 365, 1415, 10.1016/S0140-6736(05)66378-7 Expert Panel on Detection, Evaluation, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Kissebah, 1989, Health risks of obesity, Med Clin North Am, 73, 111, 10.1016/S0025-7125(16)30695-2 Pouliot, 1992, Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels, Diabetes, 41, 826, 10.2337/diabetes.41.7.826 Després, 1990, Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease, Arteriosclerosis, 10, 497, 10.1161/01.ATV.10.4.497 Lemieux, 2000, Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?, Circulation, 102, 179, 10.1161/01.CIR.102.2.179 Castelli, 1984, Epidemiology of coronary heart disease: The Framingham study, Am J Med, 76, 4, 10.1016/0002-9343(84)90952-5 Lamarche, 1998, Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease, JAMA, 279, 1955, 10.1001/jama.279.24.1955 Katon, 2003, Clinical and health services relationships between major depression, depressive symptoms, and general medical illness, Biol Psychiatry, 54, 216, 10.1016/S0006-3223(03)00273-7 Katon, 1990, Depression and chronic medical illness, J Clin Psychiatry, 51, 3 Roberts, 2000, Are the obese at greater risk for depression?, Am J Epidemiol, 152, 163, 10.1093/aje/152.2.163 Onyike, 2003, Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey, Am J Epidemiol, 158, 1139, 10.1093/aje/kwg275 Yanovski, 1993, Association of binge eating disorder and psychiatric comorbidity in obese subjects [published correction appears in Am J Psychiatry. 1993;150:1910], Am J Psychiatry, 150, 1472, 10.1176/ajp.150.10.1472 Carpenter, 2000, Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: Results from a general population study, Am J Public Health, 90, 251, 10.2105/AJPH.90.2.251 Adams, 2007, Long-term mortality after gastric bypass surgery, N Engl J Med, 357, 753, 10.1056/NEJMoa066603 Greenman, 2007, Obesity and depression, Obesity and Metabolism, 3, 206 Dansinger, 2005, Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial, JAMA, 293, 43, 10.1001/jama.293.1.43 Bellocchio, 2007, The endocannabinoid system in the regulation of cardiometabolic risk factors, Am J Cardiol, 100, 7P, 10.1016/j.amjcard.2007.10.009 Jamshidi, 2001, Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats, Br J Pharmacol, 134, 1151, 10.1038/sj.bjp.0704379 Williams, 1999, Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors, Psychopharmacology (Berl), 143, 315, 10.1007/s002130050953 Ravinet Trillou, 2003, Antiobesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, Am J Physiol Regul Integr Comp Physiol, 284, R345, 10.1152/ajpregu.00545.2002 Cota, 2003, The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis, J Clin Invest, 112, 423, 10.1172/JCI17725 Ravinet Trillou, 2004, CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity, Int J Obes Relat Metab Disord, 28, 640, 10.1038/sj.ijo.0802583 Matias, 2007, Endocannabinoids and the control of energy balance, Trends Endocrinol Metab, 18, 27, 10.1016/j.tem.2006.11.006 Poirier, 2005, The antiobesity effect of rimonabant is associated with an improved serum lipid profile, Diabetes Obes Metab, 7, 65, 10.1111/j.1463-1326.2004.00374.x National Heart, Lung, 2000 Buse, 2007, Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association, Diabetes Care, 30, 162, 10.2337/dc07-9917 Li, 2005, Meta-analysis: Pharmacologic treatment of obesity, Ann Intern Med, 142, 532, 10.7326/0003-4819-142-7-200504050-00012 Hansen, 1999, The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction, Int J Obes Relat Metab Disord, 23, 1016, 10.1038/sj.ijo.0801059 James, 2000, Sibutramine Trial of Obesity Reduction and Maintenance. Effect of sibutramine on weight maintenance after weight loss: A randomised trial, Lancet, 356, 2119, 10.1016/S0140-6736(00)03491-7 MERIDIA® (sibutramine hydrochloride monohydrate) [package insert]. Abbott Park, Ill: Abbott Laboratories; Revised October 2007. James, 2005, The SCOUT study: Risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients, Eur Heart J, 7, L44, 10.1093/eurheartj/sui086 Wadden, 2005, Randomized trial of lifestyle modification and pharmacotherapy for obesity, N Engl J Med, 353, 2111, 10.1056/NEJMoa050156 Hollander, 1998, Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study, Diabetes Care, 21, 1288, 10.2337/diacare.21.8.1288 Torgerson, 2004, XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004;27:856], Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study [published correction appears in Lancet. 2005;366:370], Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial [published correction appears in JAMA. 2006;295:1252], JAMA, 295, 761, 10.1001/jama.295.7.761 Després, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537 Scheen, 2006, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [published correction appears in Lancet. 2006;368:1650], Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8 Rucker, 2007, Long term pharmacotherapy for obesity and overweight: Updated meta-analysis [published correction appears in BMJ. 2007;335], BMJ, 335, 1194, 10.1136/bmj.39385.413113.25 Alexander, 2003, NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210 Meigs, 2003, Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies, Diabetes, 52, 2160, 10.2337/diabetes.52.8.2160 Pischon, 2004, Plasma adiponectin levels and risk of myocardial infarction in men, JAMA, 291, 1730, 10.1001/jama.291.14.1730 Spranger, 2003, Adiponectin and protection against type 2 diabetes mellitus [published correction appears in Lancet. 2003;361:1060], Lancet, 361, 226, 10.1016/S0140-6736(03)12255-6 Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405 Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992 Combs, 2001, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, J Clin Invest, 108, 1875, 10.1172/JCI14120 Fruebis, 2001, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc Natl Acad Sci U S A, 98, 2005, 10.1073/pnas.041591798 Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 7, 941, 10.1038/90984 Bensaid, 2003, The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells, Mol Pharmacol, 63, 908, 10.1124/mol.63.4.908 Christensen, 2007, Efficacy and safety of the weight-loss drug rimonabant: A metaanalysis of randomised trials [published correction appears in Lancet. 2008;371:558], Lancet, 370, 1706, 10.1016/S0140-6736(07)61721-8 US Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. June 13, 2007. Briefing Information. NDA 21-888. ZIMULTI® (rimonabant)-sanofi-aventis. http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm. Accessed July 31, 2008. Addy, 2008, The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing-energy expenditure and decreasing caloric intake, Cell Metab, 7, 68, 10.1016/j.cmet.2007.11.012 Jbilo, 2005, The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance, FASEB J, 19, 1567, 10.1096/fj.04-3177fje